Compare CBZ & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBZ | ABCL |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.5B |
| IPO Year | 1996 | 2020 |
| Metric | CBZ | ABCL |
|---|---|---|
| Price | $54.68 | $12.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $41.33 | $8.40 |
| AVG Volume (30 Days) | 1.1M | ★ 4.5M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.62 | 10.91 |
| EPS | ★ 2.83 | N/A |
| Revenue | ★ $922,003,000.00 | $75,128,000.00 |
| Revenue This Year | $3.92 | N/A |
| Revenue Next Year | $4.12 | $21.85 |
| P/E Ratio | $19.30 | ★ N/A |
| Revenue Growth | 7.79 | ★ 160.56 |
| 52 Week Low | $24.29 | $2.75 |
| 52 Week High | $56.93 | $13.18 |
| Indicator | CBZ | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 69.05 | 66.23 |
| Support Level | $54.37 | $10.38 |
| Resistance Level | $55.12 | N/A |
| Average True Range (ATR) | 0.16 | 0.63 |
| MACD | -0.36 | -0.04 |
| Stochastic Oscillator | 46.94 | 79.72 |
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the maximum of its revenues from the Financial Services segment and geographically from the United States.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.